HENDERSON, Nev., Jan. 4, 2024 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year. Volition’s major achievements in 2023 include: Launching the Nu.Q® Vet Cancer Test in some significant markets through several licensing, supply and/or distribution agreements. Establishing […]